Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Үндсэн зохиолчид: | Cree, BAC, Bennett, JL, Kim, HJ, Weinshenker, BG, Pittock, SJ, Wingerchuk, DM, Fujihara, K, Paul, F, Cutter, GR, Marignier, R, Green, AJ, Aktas, O, Hartung, H-P, Lublin, FD, Drappa, J, Barron, G, Madani, S, Ratchford, JN, She, D, Cimbora, D, Katz, E |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Elsevier
2019
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism
-н: Ho Jin Kim, зэрэг
Хэвлэсэн: (2023-12-01) -
Treatment of Neuromyelitis Optica: Review and Recommendations.
-н: Kimbrough, D, зэрэг
Хэвлэсэн: (2012) -
Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders
-н: Chu-Yuan Lou, зэрэг
Хэвлэсэн: (2024-06-01) -
Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
-н: Dominik Lehrieder, зэрэг
Хэвлэсэн: (2023-11-01) -
Treatment of neuromyelitis optica: Review and recommendations
-н: Kimbrough, D, зэрэг
Хэвлэсэн: (2012)